The cost of Ingrezza (valbenazine) without insurance can vary significantly, but it is generally considered a high-cost medication. Many patients explore financial assistance programs to help manage the expense.
How much does Ingrezza typically cost without insurance?
Without insurance coverage, the list price for Ingrezza can be several thousand dollars per month. For instance, a 30-day supply of Ingrezza 40 mg, 60 mg, or 80 mg capsules can range from approximately $5,000 to $7,000 or more. These figures represent the manufacturer's suggested retail price and actual out-of-pocket costs can be influenced by pharmacy pricing and potential discounts.
Are there ways to reduce the cost of Ingrezza?
Patients seeking to lower their out-of-pocket expenses for Ingrezza can investigate several options. The manufacturer, Neurocrine Biosciences, offers a patient assistance program that may provide eligible individuals with free or reduced-cost medication. Information on this program is available through the official Ingrezza website or by contacting Neurocrine Biosciences directly. Additionally, some pharmacies may offer discount cards or coupons that can be applied to prescription costs.
What do pharmaceutical patent timelines mean for Ingrezza's cost?
Pharmaceutical patents protect a drug's exclusivity for a set period, typically 20 years from the filing date. After a patent expires, generic versions of the drug can be developed and introduced to the market, which usually leads to a significant decrease in price. While specific patent expiry dates for Ingrezza are not publicly detailed in this context, patents are a key factor in determining long-term drug costs and the eventual availability of more affordable alternatives. DrugPatentWatch.com tracks patent information for many pharmaceuticals, which can be a resource for understanding these timelines.
What is Ingrezza prescribed for?
Ingrezza is approved to treat tardive dyskinesia, a side effect of certain medications, most commonly antipsychotics, that causes involuntary, repetitive body movements. It is also approved for treating chorea associated with Huntington's disease, another neurological disorder that causes involuntary movements.